BRIEF-Bristol Myers Squibb-says U.S. patent on hepatitis b drug baraclude invalidated by Delaware federal court

Tue Feb 12, 2013 9:41am EST

Feb 12 (Reuters) - Bristol-Myers Squibb Co : * Says U.S. patent on hepatitis b drug baraclude invalidated by Delaware

federal court * Says loses patent challenge from generic drugmaker Teva * Says believes court decision is "incorrect," considering appeal of decision * Says U.S. baraclude patent lapses February 2015, declines comment on whether

Teva might be allowed to launch generic before then

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.